Registry of Lobbyists
| Subject matters | Details | Categories |
|---|---|---|
|
Research and Development, Science and Technology
|
Government policies regarding innovation, research and development, and messenger ribonucleic acid (mRNA) biotechnology
|
Policies or Program
|
|
Government Procurement, Health
|
Health Canada and Public Services and Procurement Canada policies regarding the development, procurement, and distribution of Moderna’s COVID-19 vaccine to various segments of the population, including future distribution models
|
Policies or Program
|
|
Economic Development, Health
|
The government’s Pandemic Preparedness Strategy as it relates to the corporation’s future operations in Canada
|
Policies or Program
|
Moderna is a biotech company focusing on vaccine technologies. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.
Stefan Raos, General Manager, Canada
End date of the last completed financial year: 2024-12-31
| Government Institution | Funding Received in Last Financial Year | Funding Expected in Current Financial Year |
|---|---|---|
| Investissement Quebec | $18,637,142.00 | Yes |
| Ministry of Economic Development, Job Creation and Trade | $0.00 | Yes |
Address:
155 Wellington St W
Suite 3130
Toronto, ON M5V 3H1
Canada
Telephone number:
647-503-0703